Highlights

U.S. FDA lifts clinical hold on NUZ-001, clearing the way for Phase 2/3 HEALEY ALS Platform Trial.

IND supported by comprehensive preclinical safety data and Elanco licensing agreement manufacturing information.

Trial initiation expected in Q4 CY2025, positioning NUZ-001 for pipeline expansion and regulatory acceleration.

Neurizon Therapeutics Limited (ASX:NUZ) has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational therapy, NUZ-001. The removal of this hold allows Neurizon to advance NUZ-001 into the Phase 2/3 HEALEY ALS Platform Trial, anticipated to begin in Q4 CY2025. Following this announcement, NUZ shares gained 3.45% to trade at AUD 0.15 per share.

IND Submission Supported by Preclinical and Manufacturing Data

NUZ-001’s investigational new drug (IND) submission was supported by extensive preclinical safety data and comprehensive manufacturing and quality information derived from Neurizon’s existing licensing agreement with Elanco. The FDA’s decision validates the company’s regulatory and clinical framework for NUZ-001, establishing a foundation for both current and future therapeutic programs.

The IND clearance is designed to facilitate the development of NUZ-001 as a platform molecule, enabling potential expansion into additional indications and accelerating subsequent regulatory approvals. This provides a structured path for clinical development while maintaining flexibility for strategic pipeline growth.

Pathway to the HEALEY ALS Platform Trial

With the clinical hold lifted, Neurizon is partnering with the HEALEY ALS Platform Trial team to finalize protocol amendments at Mass General Hospital (MGH). These amendments will incorporate Neurizon’s specific protocol regimen, with patient enrollment expected to commence in Q4 CY2025.

Dr. Michael Thurn, Managing Director and CEO, stated that the FDA clearance represents a pivotal step in advancing NUZ-001 towards patients living with ALS. The investigational therapy is supported by TDP-43 preclinical data and encouraging survival outcomes from the Open-Label Extension (OLE) study in ALS patients, providing the basis for its inclusion in the platform trial.

Implications for Development and Future Opportunities

By establishing a validated regulatory framework for NUZ-001, Neurizon is able to streamline future clinical programs while reducing regulatory risk. The IND clearance enhances the molecule’s potential as a therapeutic platform, supporting accelerated development timelines and offering opportunities for strategic collaborations and partnerships.

The next steps include protocol finalisation, initiation of patient enrollment in the HEALEY ALS Platform Trial, and continued integration of preclinical and clinical data to guide further development. These milestones aim to advance patient access to innovative therapies while positioning NUZ-001 as a key candidate in Neurizon’s neurodegenerative disease portfolio.